| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Neuroimmunology Branch (Drs. Stone, Smith, McFarlin, and McFarland), the Biometry and Field Studies Branch (Dr. Albert), and the Epilepsy Research Branch (Dr. DeCarli), NINDS, NIH, Bethesda, MD; the Laboratory of Diagnostic Radiology Research Program (Dr. Frank), OD, NIH; and the Department of Radiology (Dr. Armstrong), Cornell University Medical Center, New York, NY.
Received May 20, 1994. Accepted in final form February 21, 1995.
Address correspondence and reprint requests to Dr. Lael A. Stone, Neuroimmunology Branch, NINDS, Building 10, Room 5B16, NIH, 9000 Rockville Pike, Bethesda, MD 20892.
MRI is a sensitive technique for assessing disease activity in MS.Diseased white matter (WM) can be identified on T2-weighted images, and active disease is reflected by abnormalities in the blood-brain barrier (BBB) shown on T1-weighted images after administration of paramagnetic contrast agents. Active disease may be demonstrated by contrast-enhanced MRI in patients with early, mild relapsing-remitting (RR) MS even during periods of clinical stability, which indicates that MS is an active process even during the early phase of the illness. To examine the amount of abnormal WM at frequent intervals over time, we studied seven mildly affected RRMS patients, all of whom had frequent contrast-enhancing lesions. These RRMS patients were imaged monthly for 26 to 36 months at 1.5 tesla; the area of abnormal increased WM signal was calculated by image-processing software that utilizes both the T2- and T1-weighted images. All patients showed fluctuations over time in amount of abnormal WM signal, which reflected factors such as the amount of BBB breakdown (measured by number or area of enhancing lesions) and measurement error. All seven RRMS patients, however, showed an overall increase in abnormal WM. Because of the fluctuations between individual measurements, the increase was most accurately reflected when the mean of the first 6 months' measurements was compared with the mean of the final 6 months' measurements, or when a linear regression model was applied. Although the accumulation of abnormal WM provides an additional tool for assessing disease activity in MS, its usefulness may be increased by the measurements obtained with additional techniques that are currently available or as yet undeveloped.
NEUROLOGY 1995;45: 1808-1814
This article has been cited by other articles:
|
|
 |
|
  B. Moraal, D. S. Meier, P. A. Poppe, J. J. G. Geurts, H. Vrenken, W. M. A. Jonker, D. L. Knol, R. A. van Schijndel, P. J. W. Pouwels, C. Pohl, et al. Subtraction MR Images in a Multiple Sclerosis Multicenter Clinical Trial Setting Radiology, November 26, 2008; (2008) 2501080480. [Abstract] [Full Text]
|
|
|
|
 |
|
 M.P. Wattjes, M. Harzheim, C.K. Kuhl, J. Gieseke, S. Schmidt, L. Klotz, T. Klockgether, H.H. Schild, and G.G. Lutterbey Does High-field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis? AJNR Am. J. Neuroradiol., September 1, 2006; 27(8): 1794 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, H.F. McFarland, and J. A. Frank Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN{beta}-1b Neurology, September 10, 2002; 59(5): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D Richert, M. C. Zierak, C. N Bash, B. K Lewis, H. F McFarland, and J. A Frank MRI and clinical activity in MS patients after terminating treatment with interferon beta-l b Multiple Sclerosis, April 1, 2000; 6(2): 86 - 90. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ge, R. I. Grossman, J. K. Udupa, J. Fulton, C. S. Constantinescu, F. Gonzales-Scarano, J. S. Babb, L. J. Mannon, D. L. Kolson, and J. A. Cohen Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment Neurology, February 22, 2000; 54(4): 813 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miki, R. I. Grossman, J. K. Udupa, L. Wei, M. Polansky, L. J. Mannon, and D. L. Kolson Relapsing-Remitting Multiple Sclerosis: Longitudinal Analysis of MR Images-Lack of Correlation between Changes in T2 Lesion Volume and Clinical Findings Radiology, November 1, 1999; 213(2): 395 - 399. [Abstract] [Full Text]
|
|
|
|
|
|
E. K. Jordan, H. I. McFarland, B. K. Lewis, N. Tresser, M. A. Gates, M. Johnson, M. Lenardo, L. A. Matis, H. F. McFarland, and J. A. Frank Serial MR Imaging of Experimental Autoimmune Encephalomyelitis Induced by Human White Matter or by Chimeric Myelin-Basic and Proteolipid Protein in the Common Marmoset AJNR Am. J. Neuroradiol., June 1, 1999; 20(6): 965 - 976. [Abstract] [Full Text]
|
|
|
|
|
|
M. Filippi, M. A. Rocca, C. Gasperini, M. P. Sormani, S. Bastianello, M. A. Horsfield, C. Pozzilli, and G. Comi Interscanner Variation in Brain MR Lesion Load Measurements in Multiple Sclerosis Using Conventional Spin-Echo, Rapid Relaxation-Enhanced, and Fast-FLAIR Sequences AJNR Am. J. Neuroradiol., January 1, 1999; 20(1): 133 - 137. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. J. Khoury and H. L. Weiner Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies? Arch Intern Med, March 23, 1998; 158(6): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
